The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Open accessAbstract
SUMMARY Background Colchicine has been proposed as a treatment for COVID-19 on the basis of its anti-inflammatory actions. Methods In this randomised, controlled, open-label trial, several possible treatments were compared with usual care in patients hospitalised with COVID-19. Eligible and consenting adults were randomly allocated in a 1:1 ratio to either usual standard of care alone or usual standard of care plus colchicine twice daily for 10 days or until discharge (or one of the other treatment arms) using web-based simple (unstratified) randomisation with allocation concealment. The primary outcome was 28-day mortality. The trial is registered with ISRCTN (50189673) and clinicaltrials.gov ( NCT04381936 ). Findings Between 27 November 2020 and 4 March 2021, 5610 patients were randomly allocated to receive colchicine and 5730 patients to receive usual care alone. Overall, 1173 (21%) patients allocated to colchicine and 1190 (21%) patients allocated to usual care died within 28 days (rate ratio 1.01; 95% confidence interval [CI] 0.93-1.10; p=0.77). Consistent results were seen in all pre-specified subgroups of patients. There was no significant difference in duration of hospitalisation (median 10 days vs. 10 days) or the proportion of patients discharged from hospital alive within 28 days (70% vs. 70%; rate ratio 0.98; 95% CI 0.94-1.03; p=0.44). Among those not on invasive mechanical ventilation at baseline, there was no significant difference in the proportion meeting the composite endpoint of invasive mechanical ventilation or death (25% vs. 25%; risk ratio 1.02; 95% CI 0.96-1.09; p=0.47). Interpretation In adults hospitalised with COVID-19, colchicine was not associated with reductions in 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death. Funding UK Research and Innovation (Medical Research Council) and National Institute of Health Research (Grant ref: MC_PC_19056). Wellcome Trust (Grant Ref: 222406/Z/20/Z) through the COVID-19 Therapeutics Accelerator.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
Endothelial cell infection and endotheliitis in COVID-19
Varga, Z., Flammer, A. J., Steiger, P., Haberecker, M., Andermatt, R., Zinkernagel, A. S., Mehra, M. R., Schuepbach, R. A., Ruschitzka, F., & Moch, H. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30937-5 · Cited by 6,358
Ruan, Q., Yang, K., Wang, W., Jiang, L., & Song, J. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05991-x · Cited by 4,898
Efficacy and safety of low-dose colchicine after myocardial infarction
Tardif, J.-C., Kouz, S., Waters, D. D., Bertrand, O. F., Diaz, R., Maggioni, A. P., Pinto, F. J., Ibrahim, R., Gamra, H., Kiwan, G. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1912388 · Cited by 3,159
The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne, J. A. C., Murthy, S., Diaz, J. V., Slutsky, A. S., Villar, J., Angus, D. C., Annane, D., Azevedo, L. C. P., Berwanger, O., et al. (2020) · JAMA · doi:10.1001/jama.2020.17023 · Cited by 2,257
Self-citationRodrigues, T. S., de Sá, K. S. G., Ishimoto, A. Y., Becerra, A., Oliveira, S., Almeida, L., Gonçalves, A. V., Perucello, D. B., Andrade, W. A., Castro, R., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201707 · Cited by 839
Skendros, P., Mitsios, A., Chrysanthopoulou, A., Mastellos, D. C., Metallidis, S., Rafailidis, P., Ntinopoulou, M., Sertaridou, E., Tsironidou, V., Tsigalou, C., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci141374 · Cited by 786
A Randomized Trial of Colchicine for Acute Pericarditis
Imazio, M., Brucato, A., Cemin, R., Ferrua, S., Maggiolini, S., Beqaraj, F., Demarie, D., Forno, D., Ferro, S., Maestroni, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208536 · Cited by 611
Research works printed but not linked: 20
- Huang, 2020, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, 395, 497, 10.1016/S0140-6736(20)30183-5 · DOI · Paper page
- Wang, 2021, Inflammation-associated factors for predicting in-hospital mortality in patients with COVID-19, J Med Virol, 93, 2908, 10.1002/jmv.26771 · DOI
- Thwaites, 2021, Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19, Sci Immunol, 6, eabg9873, 10.1126/sciimmunol.abg9873 · DOI · Paper page
- McElvaney, 2020, Characterization of the inflammatory response to severe COVID-19 illness, Am J Respir Crit Care Med, 202, 812, 10.1164/rccm.202005-1583OC · DOI · Paper page
- Dorward, 2021, Tissue-specific immunopathology in fatal COVID-19, Am J Respir Crit Care Med, 203, 192, 10.1164/rccm.202008-3265OC · DOI · Paper page
- 2021, Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Lancet, 397, 1637, 10.1016/S0140-6736(21)00676-0 · DOI · Paper page
- Kalil, 2020, Baricitinib plus remdesivir for hospitalized adults with Covid-19, N Engl J Med, 384, 795, 10.1056/NEJMoa2031994 · DOI · Paper page
- Broz, 2016, Inflammasomes: mechanism of assembly, regulation and signalling, Nat Rev Immunol, 16, 407, 10.1038/nri.2016.58 · DOI · Paper page
- Dalbeth, 2014, Mechanism of action of colchicine in the treatment of gout, Clin Ther, 36, 1465, 10.1016/j.clinthera.2014.07.017 · DOI · Paper page
- Fiolet, 2021, Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials, Eur Heart J, 42, 2765, 10.1093/eurheartj/ehab115 · DOI · Paper page
- Martinez, 2018, The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation, Atherosclerosis, 269, 262, 10.1016/j.atherosclerosis.2017.12.027 · DOI · Paper page
- Salehzadeh, 2020, The impact of colchicine on the COVID-19 patients; a clinical trial study, Research Square
- Lopes, 2021, Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial, RMD Open, 7, e001455, 10.1136/rmdopen-2020-001455 · DOI · Paper page
- Deftereos, 2020, Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial, JAMA Netw Open, 3, e2013136, 10.1001/jamanetworkopen.2020.13136 · DOI · Paper page
- Horby, 2020, Effect of hydroxychloroquine in hospitalized patients with Covid-19, N Engl J Med, 383, 2030, 10.1056/NEJMoa2022926 · DOI · Paper page
- 2020, Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Lancet, 396, 1345, 10.1016/S0140-6736(20)32013-4 · DOI · Paper page
- 2021, Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Lancet, 397, 605, 10.1016/S0140-6736(21)00149-5 · DOI · Paper page
- 2021, Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Lancet, 397, 2049, 10.1016/S0140-6736(21)00897-7 · DOI · Paper page
- Deftereos, 2020, The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): rationale and study design, Hellenic J Cardiol, 61, 42, 10.1016/j.hjc.2020.03.002 · DOI
- Tardif, 2021, Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial, Lancet Respir Med, 9, 924, 10.1016/S2213-2600(21)00222-8 · DOI · Paper page
Cited by
Abaleke, E., Abbas, M., Abbasi, S., Abbott, A., Abdelaziz, A., Abdelbadiee, S., Abdelfattah, M., Abdul, B., Abdul Rasheed, A., Abdul-Kadir, R., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00149-5 · Cited by 533
Cytokine Storm in COVID-19: Immunopathogenesis and Therapy
Zanza, C., Romenskaya, T., Manetti, A., Franceschi, F., La Russa, R., Bertozzi, G., Maiese, A., Savioli, G., Volonnino, G., & Longhitano, Y. (2022) · Medicina · doi:10.3390/medicina58020144 · Cited by 381
Abani, O., Abbas, A., Abbas, F., Abbas, M., Abbasi, S., Abbass, H., Abbott, A., Abdallah, N., Abdelaziz, A., Abdelfattah, M., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00163-5 · Cited by 369
Abani, O., Abbas, A., Abbas, F., Abbas, J., Abbas, K., Abbas, M., Abbasi, S., Abbass, H., Abbott, A., Abbott, A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01109-6 · Cited by 324
Abani, O., Abbas, A., Abbas, F., Abbas, M., Abbasi, S., Abbass, H., Abbott, A., Abdallah, N., Abdelaziz, A., Abdelfattah, M., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01825-0 · Cited by 290
Metadata
- Venue
- The Lancet Respiratory Medicine
- Publisher
- Elsevier BV
- Published
- 2021-12
- Volume
- 9
- Issue
- 12
- Pages
- 1419-1426
- ISSN
- 2213-2600 (ISSN-L)
- OpenAlex
- W4226264587
- Cited by
- 211
- References
- 8
- FWCI
- 13.92
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Funders
- Department of Health and Social Care (COVID-19)
- Roche
- Public Health England
- Bill and Melinda Gates Foundation
- UK Research and Innovation
- Medical Research Council (MC_PC_19056, MC_UU_0002/14)
- Swansea University
- Wellcome Trust (222406/Z/20/Z)
- National Institute for Health Research
- NIHR Oxford Biomedical Research Centre
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. https://app.cochat.ai/papers/10.1016/s2213-2600(21)00435-5
- The paper
- Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. (2021). The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(21)00435-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.